November 19, 2021 |
Mexico's Genomma Lab International may have to raise debt to produce enough COVID-19 vaccines to meet demand in Latin America following the creation of a joint venture with Israel's Oramed Pharmaceuticals.
"Possibly, once the vaccine is authorized and we have orders of a magnitude in the 10s of millions, we would need to raise some debt," Rodrigo Herrera, founder and chairman of Genomma Lab, told LatinFinance on Thursday. "That would be the least of all our problems, but we are not planning to r
Mexican pharmaceutical company forms a JV with Israel's Oramed to make and market oral COVID-19 vaccines in Latin America